Free Cash Flow for Vertex Pharmaceuticals (VRTX)
Free Cash Flow for Vertex Pharmaceuticals (VRTX): headline value $3.19B · YoY -504.1%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingFree Cash FlowSwitch metric
Latest period
$3.19B
YoY change
-504.1%
5Y CAGR
+1.3%
Peak year (2022)
$3.93B
Latest annual
$3.19B
Free Cash Flow history chart for Vertex Pharmaceuticals (VRTX) from 1991 to 2025
Free Cash Flow history table for Vertex Pharmaceuticals (VRTX) from 1991 to 2025
| Fiscal year | Period ended | Reported | Free Cash Flow | YoY |
|---|---|---|---|---|
| 2025 | $3.19B | -504.1% | ||
| 2024 | -$790.30M | -124.1% | ||
| 2023 | $3.28B | -16.5% | ||
| 2022 | $3.93B | +63.0% | ||
| 2021 | $2.41B | -19.5% | ||
| 2020 | $2.99B | +100.4% | ||
| 2019 | $1.49B | +27.2% | ||
| 2018 | $1.17B | +100.6% | ||
| 2017 | $585.52M | +226.1% | ||
| 2016 | $179.54M | -143.7% | ||
| 2015 | -$410.73M | -27.2% | ||
| 2014 | -$564.40M | +448.2% | ||
| 2013 | -$102.96M | -152.3% | ||
| 2012 | $196.70M | +300.3% | ||
| 2011 | $49.14M | -107.3% | ||
| 2010 | -$673.50M | +49.3% | ||
| 2009 | -$451.08M | +74.4% | ||
| 2008 | -$258.66M | -9.2% | ||
| 2007 | -$284.89M | +419.0% | ||
| 2006 | -$54.89M | -71.0% | ||
| 2005 | -$189.01M | +22.2% | ||
| 2004 | -$154.66M | -16.4% | ||
| 2003 | -$184.97M | +53.2% | ||
| 2002 | -$120.76M | +94.9% | ||
| 2001 | -$61.97M | +117.0% | ||
| 2000 | -$28.56M | -40.5% | ||
| 1999 | -$48.00M | +23.1% | ||
| 1998 | -$39.00M | +153.2% | ||
| 1997 | -$15.40M | -65.2% | ||
| 1996 | -$44.30M | +107.0% | ||
| 1995 | -$21.40M | +28.9% | ||
| 1994 | -$16.60M | -344.1% | ||
| 1993 | $6.80M | -200.0% | ||
| 1992 | -$6.80M | +83.8% | ||
| 1991 | -$3.70M | — |
Free Cash Flow values are taken from Vertex Pharmaceuticals's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of Vertex Pharmaceuticals (VRTX) free cash flow is $3.19B – plunged 504.1% year-over-year.
Vertex Pharmaceuticals free cash flow compound annual growth for the 2020–2025 (5 years) window is +1.3%, with the latest reading among the more recent periods of the dataset.
Vertex Pharmaceuticals free cash flow peaked at $3.93B in 2022; the latest annual figure is $3.19B in 2025 (18.6% below peak).
2022 marks the peak free cash flow at $3.93B, with the historical low of -$790.30M recorded in 2024.
Within Healthcare, Vertex Pharmaceuticals (VRTX) ranks 9th among 8 peers we track. The peer median for free cash flow is $14.22B.
Vertex Pharmaceuticals Free Cash Flow by Year
Vertex Pharmaceuticals Free Cash Flow 2025: $3.19B
Vertex Pharmaceuticals free cash flow in 2025 was $3.19B, plunged 504.1% below 2024.
Vertex Pharmaceuticals Free Cash Flow 2024: -$790.30M
Vertex Pharmaceuticals free cash flow in 2024 was -$790.30M, plunged 124.1% below 2023. This figure represents the lowest annual value in the available history.
Vertex Pharmaceuticals Free Cash Flow 2023: $3.28B
Vertex Pharmaceuticals free cash flow in 2023 was $3.28B, declined 16.5% below 2022.
Vertex Pharmaceuticals Free Cash Flow 2022: $3.93B
Vertex Pharmaceuticals free cash flow in 2022 was $3.93B, surged 63.0% from 2021. This figure represents the highest annual value in the available history.
Vertex Pharmaceuticals Free Cash Flow 2021: $2.41B
Vertex Pharmaceuticals free cash flow in 2021 was $2.41B.
See more financial history for Vertex Pharmaceuticals (VRTX).
Sector peers — Free Cash Flow
Companies in the same sector as Vertex Pharmaceuticals, ranked by their latest free cash flow.
| Company | Free Cash Flow | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $28.99B | Healthcare |
| Johnson & Johnson (JNJ) | $19.70B | Healthcare |
| AbbVie Inc. (ABBV) | $17.82B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $16.07B | Healthcare |
| Merck & Co., Inc. (MRK) | $12.36B | Healthcare |
| AstraZeneca PLC (AZN) | $11.77B | Healthcare |
| Eli Lilly and Company (LLY) | $8.97B | Healthcare |
| Amgen Inc. (AMGN) | $8.10B | Healthcare |
Frequently asked questions
What is Vertex Pharmaceuticals's free cash flow?
Latest reported free cash flow for Vertex Pharmaceuticals (VRTX) is $3.19B (period ending December 31, 2025).
How has Vertex Pharmaceuticals free cash flow changed year-over-year?
Vertex Pharmaceuticals (VRTX) free cash flow changed -504.1% year-over-year on the latest annual filing.
What is the long-term growth rate of Vertex Pharmaceuticals free cash flow?
Vertex Pharmaceuticals (VRTX) free cash flow compound annual growth rate is +1.3% over the most recent 5 years available.
When did Vertex Pharmaceuticals free cash flow hit its highest annual value?
Vertex Pharmaceuticals free cash flow reached its highest annual value of $3.93B in 2022.
What was Vertex Pharmaceuticals free cash flow in 2024?
Vertex Pharmaceuticals (VRTX) free cash flow in 2024 was -$790.30M.
What was Vertex Pharmaceuticals free cash flow in 2025?
Vertex Pharmaceuticals (VRTX) free cash flow in 2025 was $3.19B.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
VRTX Overview
Company profile, financial tools, and key metrics
VRTX Revenue Counter
Earns $381.74 every second. See per minute, hour, and day.
VRTX Earnings Counter
Earns $125.36 per second net profit. See per minute, hour, and day.
VRTX Economic Scale
Exceeds Somalia, Fed. Rep.'s GDP. Compare with world economies.
VRTX What If Invested
What if you had invested $1,000? See historical returns from any date.
VRTX How It Makes Money
Discover visual breakdown of $12.04B in revenue — where it comes from and where it goes.
VRTX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
VRTX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
VRTX Daily Price Character
Explosive · 48.3% historical win rate (green days). Streaks & record days.
VRTX Buybacks
1.75% TTM buyback yield. Shareholder yield & SBC comparison.
VRTX Stock Split History
1 split on record. Dates, ratios, and cumulative multiple.